JP2013121353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013121353A5 JP2013121353A5 JP2013006880A JP2013006880A JP2013121353A5 JP 2013121353 A5 JP2013121353 A5 JP 2013121353A5 JP 2013006880 A JP2013006880 A JP 2013006880A JP 2013006880 A JP2013006880 A JP 2013006880A JP 2013121353 A5 JP2013121353 A5 JP 2013121353A5
- Authority
- JP
- Japan
- Prior art keywords
- binding site
- antibody
- amino acid
- domain
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 38
- 102000036639 antigens Human genes 0.000 claims 38
- 108091007433 antigens Proteins 0.000 claims 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229940127121 immunoconjugate Drugs 0.000 claims 6
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 102000016359 Fibronectins Human genes 0.000 claims 3
- 108010067306 Fibronectins Proteins 0.000 claims 3
- 102000001708 Protein Isoforms Human genes 0.000 claims 3
- 108010029485 Protein Isoforms Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000000844 anti-bacterial effect Effects 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90958007P | 2007-04-02 | 2007-04-02 | |
| US60/909,580 | 2007-04-02 | ||
| US94856407P | 2007-07-09 | 2007-07-09 | |
| US60/948,564 | 2007-07-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501612A Division JP5221641B2 (ja) | 2007-04-02 | 2008-03-31 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013121353A JP2013121353A (ja) | 2013-06-20 |
| JP2013121353A5 true JP2013121353A5 (https=) | 2014-05-22 |
| JP5840631B2 JP5840631B2 (ja) | 2016-01-06 |
Family
ID=39791007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501612A Expired - Fee Related JP5221641B2 (ja) | 2007-04-02 | 2008-03-31 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
| JP2013006880A Active JP5840631B2 (ja) | 2007-04-02 | 2013-01-18 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501612A Expired - Fee Related JP5221641B2 (ja) | 2007-04-02 | 2008-03-31 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US8263041B2 (https=) |
| EP (2) | EP2653478B1 (https=) |
| JP (2) | JP5221641B2 (https=) |
| KR (1) | KR101515243B1 (https=) |
| CN (2) | CN101687923B (https=) |
| AU (1) | AU2008234615B2 (https=) |
| BR (1) | BRPI0809989B8 (https=) |
| CA (1) | CA2682851C (https=) |
| EA (2) | EA036322B1 (https=) |
| ES (2) | ES2402171T3 (https=) |
| MX (1) | MX2009010639A (https=) |
| WO (1) | WO2008120101A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2817005B2 (ja) | 1990-06-29 | 1998-10-27 | スズキ株式会社 | エンジン用オーバヒート検出装置 |
| WO2008120101A2 (en) | 2007-04-02 | 2008-10-09 | Philogen S.P.A. | The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases |
| US10202442B2 (en) | 2007-07-25 | 2019-02-12 | Philogen S.P.A. | Antigen associated with lung cancers and lymphomas |
| EP2167541B1 (en) * | 2007-07-25 | 2012-12-19 | Philogen S.p.A. | The ed-a antigen of fibronectin is associated with the neovasculature of tumour metastases |
| DK3281952T3 (da) | 2007-10-30 | 2020-08-03 | Philogen Spa | Antigen, der er forbundet med reumatoid artritis |
| CA2748401C (en) | 2009-01-07 | 2017-09-12 | Philogen S.P.A. | Antigens associated with endometriosis |
| US20110318302A1 (en) | 2009-01-07 | 2011-12-29 | Kathrin Schwager | Cancer Treatment |
| EP2461832B1 (en) | 2009-08-05 | 2017-06-28 | Philogen S.p.A. | Targeting of bone marrow neovasculature |
| WO2011156639A1 (en) * | 2010-06-10 | 2011-12-15 | The Regents Of The University Of California | Eiiia and eiiib segments of fibronectin regulate stem cell fate |
| JP5548872B2 (ja) * | 2010-08-26 | 2014-07-16 | 株式会社島津製作所 | 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法 |
| BR112013007160A2 (pt) | 2010-09-29 | 2016-06-14 | Philogen Spa | ligante tiazolidina para a conjugação de fármacos a anticorpos |
| ES2872964T3 (es) | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| ES2743423T3 (es) | 2012-10-03 | 2020-02-19 | Philogen Spa | Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal |
| CN106170496B (zh) | 2013-12-12 | 2019-10-08 | Umc乌得勒支控股有限公司 | 针对纤连蛋白-eda的免疫球蛋白样分子 |
| GB201507908D0 (en) | 2015-05-08 | 2015-06-24 | Philogen Spa | IL2 and TNF immunoconjugates |
| CR20180087A (es) | 2015-07-16 | 2018-05-14 | Philogen Spa | Inmunoconjugados de il22 |
| ES3007557T3 (en) | 2016-10-17 | 2025-03-20 | Pfizer | Anti-edb antibodies and antibody-drug conjugates |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| CN110997718B (zh) | 2017-06-07 | 2023-11-10 | 菲洛根股份公司 | 血管内皮生长因子/抗纤连蛋白抗体融合蛋白 |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| EP3660039A1 (en) | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2 immunoconjugates |
| WO2020070150A1 (en) | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
| WO2020247973A1 (en) * | 2019-06-03 | 2020-12-10 | The University Of Chicago | Methods and compositions for treating cancer with cancer-targeted adjuvants |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| CN114258400A (zh) | 2019-08-15 | 2022-03-29 | 詹森生物科技公司 | 用于改进的单链可变片段的材料和方法 |
| EP4185615A1 (en) | 2020-07-22 | 2023-05-31 | Philogen S.p.A. | Treatment of pulmonary hypertension |
| CN114350518B (zh) * | 2022-01-19 | 2023-01-13 | 广东乾晖生物科技有限公司 | 仿生肝微流控细胞培养-药物筛选芯片 |
| WO2023175077A1 (en) | 2022-03-17 | 2023-09-21 | Philogen S.P.A | Anti-ed-a antibodies for the treatment of pulmonary hypertension |
| WO2026003203A1 (en) | 2024-06-27 | 2026-01-02 | Philogen S.P.A. | Combination of an immunocytokine comprising targeted il2 and a jak inhibitor |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
| FI892197A7 (fi) * | 1989-05-08 | 1990-11-09 | Locus Oy | Foerfarande foer detektering av tumoerer. |
| US5420012A (en) * | 1989-05-08 | 1995-05-30 | Locus Genex Oy | Method for the detection of reactive conditions |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992017604A1 (fr) * | 1991-03-26 | 1992-10-15 | Otsuka Pharmaceutical Factory, Inc. | Anticorps monoclonal anti-eda |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| US5644033A (en) | 1992-12-22 | 1997-07-01 | Health Research, Inc. | Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment |
| DK1137941T4 (da) | 1998-12-10 | 2014-01-06 | Brystol Myers Squibb Company | Protein-scaffolds til antistof-mimetika og andre bindingsproteiner |
| AU2001239470A1 (en) | 2000-02-24 | 2001-09-03 | Philogen S.R.L. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| WO2001076630A1 (en) | 2000-04-06 | 2001-10-18 | Kyowa Hakko Kogyo Co., Ltd. | Diagnostics and remedies for rheumatoid arthritis |
| WO2001083816A2 (en) | 2000-05-04 | 2001-11-08 | Philogen S.R.L. | Method for detecting tumors |
| CN1246333C (zh) | 2000-09-07 | 2006-03-22 | 舍林股份公司 | EDb－纤粘连蛋白结构域(II)的受体 |
| IT1317108B1 (it) | 2000-12-06 | 2003-05-26 | Philogen Srl | Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso. |
| EP1224943A1 (en) | 2001-01-19 | 2002-07-24 | Crucell Holland B.V. | Fibronectin as a tumor marker detected by phage antibodies |
| MXPA04006517A (es) * | 2002-01-03 | 2005-03-31 | Schering Ag | Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores. |
| AU2003238284A1 (en) | 2002-06-21 | 2004-01-06 | Duke University | Anti-tenascin antibody fragments and minibodies for treatment of lymphoma |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| US7560095B2 (en) | 2003-04-22 | 2009-07-14 | A & G Pharmaceutical, Inc. | Cancer specific monoclonal antibodies |
| WO2005009366A2 (en) | 2003-07-24 | 2005-02-03 | Cornell Research Foundation, Inc. | Restoring vascular function |
| EP1660519B1 (en) | 2003-07-29 | 2014-05-14 | Immunomedics, Inc. | Conjugates comprising 2-[18F]fluoro-2-deoxy-D-glucose and a peptide molecule |
| JP2008514900A (ja) * | 2004-07-30 | 2008-05-08 | アデザ・バイオメデイカル・コーポレイシヨン | 疾病および他の状態のマーカーとしての癌胎児性フィブロネクチンならびに癌胎児性フィブロネクチンの検出のための方法 |
| US7785591B2 (en) * | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| AU2005304031B2 (en) | 2004-11-09 | 2009-04-23 | Philogen Spa | Antibodies against tenascin-C |
| CA2607954A1 (en) | 2005-05-11 | 2006-11-16 | Philogen S.P.A. | Conjugate for targeting of drug |
| CA2648484A1 (en) | 2006-05-08 | 2007-11-15 | Philogen Spa | Antibody-targeted cytokines for therapy |
| WO2008120101A2 (en) * | 2007-04-02 | 2008-10-09 | Philogen S.P.A. | The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases |
| EP2167541B1 (en) | 2007-07-25 | 2012-12-19 | Philogen S.p.A. | The ed-a antigen of fibronectin is associated with the neovasculature of tumour metastases |
| DK3281952T3 (da) * | 2007-10-30 | 2020-08-03 | Philogen Spa | Antigen, der er forbundet med reumatoid artritis |
| CA2748401C (en) * | 2009-01-07 | 2017-09-12 | Philogen S.P.A. | Antigens associated with endometriosis |
| BR112013007160A2 (pt) * | 2010-09-29 | 2016-06-14 | Philogen Spa | ligante tiazolidina para a conjugação de fármacos a anticorpos |
| ES2872964T3 (es) * | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| WO2014174105A1 (en) * | 2013-04-25 | 2014-10-30 | Philochem Ag | Antibody-drug conjugates |
| CA2910044A1 (en) * | 2013-04-26 | 2014-10-30 | Philogen S.P.A. | Il4 conjugated to antibodies against extracellular matrix components |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2008
- 2008-03-31 WO PCT/IB2008/000965 patent/WO2008120101A2/en not_active Ceased
- 2008-03-31 ES ES08737486T patent/ES2402171T3/es active Active
- 2008-03-31 EP EP12195343.4A patent/EP2653478B1/en active Active
- 2008-03-31 CA CA2682851A patent/CA2682851C/en active Active
- 2008-03-31 EP EP08737486A patent/EP2142567B1/en not_active Not-in-force
- 2008-03-31 KR KR1020097022770A patent/KR101515243B1/ko active Active
- 2008-03-31 BR BRPI0809989A patent/BRPI0809989B8/pt not_active IP Right Cessation
- 2008-03-31 EA EA201301224A patent/EA036322B1/ru not_active IP Right Cessation
- 2008-03-31 US US12/593,872 patent/US8263041B2/en active Active
- 2008-03-31 EA EA200970909A patent/EA018985B1/ru not_active IP Right Cessation
- 2008-03-31 CN CN2008800183109A patent/CN101687923B/zh active Active
- 2008-03-31 CN CN201310167446.9A patent/CN103275220B/zh active Active
- 2008-03-31 ES ES12195343.4T patent/ES2609813T3/es active Active
- 2008-03-31 MX MX2009010639A patent/MX2009010639A/es active IP Right Grant
- 2008-03-31 AU AU2008234615A patent/AU2008234615B2/en active Active
- 2008-03-31 JP JP2010501612A patent/JP5221641B2/ja not_active Expired - Fee Related
-
2012
- 2012-08-09 US US13/570,945 patent/US8481684B2/en active Active
-
2013
- 2013-01-18 JP JP2013006880A patent/JP5840631B2/ja active Active
- 2013-06-06 US US13/911,815 patent/US20130266511A1/en not_active Abandoned
- 2013-07-03 US US13/935,171 patent/US9181347B2/en active Active
-
2015
- 2015-10-05 US US14/874,923 patent/US9896503B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013121353A5 (https=) | ||
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| IL299072A (en) | Antibodies and methods for using them | |
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| RU2013115891A (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| JP2011502137A5 (https=) | ||
| JP2010523541A5 (https=) | ||
| JP2021501744A5 (https=) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| HRP20221141T1 (hr) | Anti-lag3 protutijela | |
| JP2016135783A5 (https=) | ||
| JP2017530092A5 (https=) | ||
| JP2012034692A5 (https=) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| NZ603529A (en) | Antibodies to human gdf8 | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| HRP20201091T1 (hr) | Protutijela anti-axl | |
| CO6331344A2 (es) | Anticuerpos aislados que unen a vegf, composiciones farmaceuticas que los comprenden y un portador farmaceuticamente aceptable y usos de los mismos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
| JP2010534237A5 (https=) |